/AIM
AIM Stock - AIM ImmunoTech Inc.
Healthcare|BiotechnologyAMEX
$1.42+4.36%
+$0.06 (+4.36%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.56
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AIM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.41 – $1.43
TARGET (TP)$1.63
STOP LOSS$1.31
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$36.00
52W Low$1.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $170,000 | $202,000 | $141,000 | $135,000 | $163,000 |
| Gross Profit | $139,000 | $160,000 | $565,000 | $-715,000 | $-643,000 |
| Gross Margin | 81.8% | 79.2% | 400.7% | -529.6% | -394.5% |
| Operating Income | $-19,772,000 | $-31,916,000 | $-19,922,810 | $-18,838,000 | $-15,152,000 |
| Net Income | $-17,320,000 | $-28,962,000 | $-19,445,000 | $-19,127,000 | $-14,400,000 |
| Net Margin | -10188.2% | -14337.6% | -13790.8% | -14168.1% | -8834.4% |
| EPS | $-0.31 | $-0.60 | $-0.44 | $-0.45 | $-0.51 |
Company Overview
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AIMBeat Rate
22%
Last 18 quarters
Avg Surprise
-8052.5%
EPS vs Estimate
Beats / Misses
4/14
Last 12 quarters
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
-17233.3%
$-26.00vs$-0.15
Q2 24
-10809.1%
$-12.00vs$-0.11
Q3 24
-2400.0%
$-3.00vs$-0.12
Q4 24
+40.0%
$-6.00vs$-10.00
Q1 25
-11.1%
$-10.00vs$-9.00
Q2 25
+37.5%
$-5.00vs$-8.00
Q3 25
+54.0%
$-3.68vs$-8.00
Q4 25
+67.3%
$-0.32vs$-0.98
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.98 | — | — | — |
Q4 2025 | Nov 17, 2025 | $-0.98 | $-0.32 | +67.3% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-8.00 | $-3.68 | +54.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-8.00 | $-5.00 | +37.5% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-9.00 | $-10.00 | -11.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-10.00 | $-6.00 | +40.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.12 | $-3.00 | -2400.0% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.11 | $-12.00 | -10809.1% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.15 | $-26.00 | -17233.3% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.11 | $-16.00 | -14445.5% | ✗ MISS |
Q3 2023 | Aug 15, 2023 | $-0.11 | $-10.00 | -8990.9% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.11 | $-8.00 | -7172.7% | ✗ MISS |
Q2 2023 | Apr 3, 2023 | $-0.12 | $-9.00 | -7400.0% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-0.08 | $-13.00 | -16150.0% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.07 | $-10.00 | -14185.7% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.07 | $-8.00 | -11328.6% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.08 | $-12.00 | -14900.0% | ✗ MISS |
Q4 2021 | Nov 16, 2021 | $-0.07 | $-8.00 | -11328.6% | ✗ MISS |
Q3 2021 | Aug 17, 2021 | — | $-12.00 | — | — |
Q2 2021 | May 18, 2021 | $-0.09 | $-8.00 | -8788.9% | ✗ MISS |
Latest News
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $22
➖ NeutralBenzinga•Dec 8, 2025, 10:33 AM
AIM ImmunoTech Enters Note Purchase Agreement For $3.3M Unsecured Promissory Note With Streeterville Capital In Private Placement
📈 PositiveBenzinga•Nov 19, 2025, 12:11 PM
AIM ImmunoTech Q3 EPS $(1.57) Misses $(0.98) Estimate, Sales $26.000K Down From $35.000K YoY
📉 NegativeBenzinga•Nov 18, 2025, 01:57 PM
AIM ImmunoTech Presents Data From Phase 2 Advanced Recurrent Ovarian Cancer Clinical Trial Across 27 Participants
📈 PositiveBenzinga•Nov 10, 2025, 02:01 PM
AIM ImmunoTech Says Data From Completed Phase 2 Cisplatin-Resistant Advanced Recurrent Ovarian Cancer Clinical Study Utilizing Ampligen Accepted In Late-Breaking Abstract At Annual SITC Meeting
📈 PositiveBenzinga•Nov 4, 2025, 02:08 PM
AIM ImmunoTech Granted European Patent For Ampligen In Long COVID Treatment
📈 PositiveBenzinga•Nov 3, 2025, 01:57 PM
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $24
📈 PositiveBenzinga•Oct 3, 2025, 10:19 AM
AIM ImmunoTech Secures Japanese Patent For Ampligen In Combination With Checkpoint Inhibitors For The Treatment Of Cancer.
📈 PositiveBenzinga•Sep 25, 2025, 12:46 PM
AIM ImmunoTech Has Been Granted European Patent Number EP4096675 Titled "COMPOSITIONS FOR TREATING LONG COVID"
📈 PositiveBenzinga•Sep 22, 2025, 07:58 PM
AIM ImmunoTech Says JITC Publishes New Peer-Reviewed Article Providing Evidence Of Combination Effect Of AIM's Drug Ampligen And Interferon-Alpha On Tumor Growth And Subsequent Subject Survival
📈 PositiveBenzinga•Sep 22, 2025, 01:05 PM
AIM ImmunoTech announces pricing of $8 million public offering; shares down over 50%
📉 NegativeSeeking Alpha•Jul 29, 2025, 01:10 PM
AIM ImmunoTech slumps 50% after pricing $8M securities offering
📉 NegativeSeeking Alpha•Jul 29, 2025, 01:10 PM
Frequently Asked Questions about AIM
What is AIM's current stock price?
AIM ImmunoTech Inc. (AIM) is currently trading at $1.42 per share. The stock has moved +4.36% today.
What is the analyst price target for AIM?
No analyst price targets are currently available for this stock.
What sector is AIM ImmunoTech Inc. in?
AIM ImmunoTech Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is AIM's market cap?
AIM ImmunoTech Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does AIM pay dividends?
No, AIM ImmunoTech Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
KALA
KALA BIO, Inc.
$0.62
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.88
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
XTLB
XTL Biopharmaceuticals Ltd.
$0.82
Mkt Cap: $0.0B
Explore stocks similar to AIM for comparison